Investigating CAR-T Efficacy Limitations in Chronic Lymphocytic Leukemia
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
Bone Cancer
BONE CANCER ADVISOR
FEATURED CONTENT
-
-
Navigating COVID-19: Self-Care Strategies for Oncology Professionals
A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves. -
Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results. -
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient. -
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
BONE CANCER NEWS
Strontium89 Now Available for Relief of Metastatic Bone Pain
FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma
CTA Treatment Regimen Chart for Bone Cancer Updated
Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma
In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy
Want to read more?
Please login or register first to view this content.
Next post in Bone Cancer
